Studies investigating dupilumab in treating allergic bronchopulmonary aspergillosis (ABPA)
| Author [ref.] | Type of study | Patients n | Sex (M:F) | Age (years) | Cystic fibrosis (yes/no) | ABPA (yes/no) | Reason for dupilumab administration | Objectives | Dupilumab dosage | Treatment duration | Follow-up | Results | Benefit (yes/no) |
| Eraso [50] | Review | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
| Ramonell [46] | Case series | 3 | 1:2 | 33–60 | No | Yes | Poor response to CSS CSS dependence Incomplete response to omalizumab and/or mepolizumab | NS | NS | 6 months | NS | Symptoms resolution No exacerbations CSS use reduction/suspension ↑ FEV1 ↓ total IgE ↑ AEC (2/3) A patient hospitalised for asthma exacerbation probably due to dupilumab-induced hypereosinophilia | Yes |
| Mümmler [45] | Case report | 1 | 0:1 | 49 | No | Yes | CSS side-effects CSS dependence Incomplete or no response to benralizumab and omalizumab | NS | 600 mg loading dose, then 300 mg s.c. every 2 weeks | 8 months | NS | Symptom improvement Oral CSS suspension ↑ FEV1 ↓ FENO ↓ total IgE ↑ AEC (transient) | Yes |
| Ali [47] | Case report | 1 | 0:1 | 60 | No | Yes | CSS side-effects CSS dependence Omalizumab hypersensitivity reaction | NS | 300 mg s.c. every 2 weeks | 4 months | NS | Symptoms improvement ↓ oral CSS ↓ total IgE | Yes |
| Mikura [48] | Case report | 1 | 1:0 | 45 | No | Yes | CSS dependence No improvement with mepolizumab | NS | 600 mg loading dose, then 300 mg s.c. every 2 weeks | 12 months | NA | Oral CSS suspension Radiological resolution ↓ total IgE | Yes |
| Nishimura [49] | Case report | 1 | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA |
M: male; F: female; NA: not applicable; CSS: corticosteroids; s.c.: subcutaneous; NS: not specified; AEC: absolute eosinophil count; FENO: fractional exhaled nitric oxide.